Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of imlifidase-enabled kidney transplantation with concurrent reference cohort
2022-502727-21-00Phase 3Authorised
- Sponsor
- Hansa Biopharma
- Start
- Jul 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, open-label trial of efgartigimod alfa in end-stage kidney disease (ESKD) (2 cohorts), sponsored by Hansa Biopharma. Primary endpoint: Graft failure-free survival up to 5 years after imlifidase-enabled transplantation. Planned start Jul 2023; status: authorised.
02
Drugs
efgartigimod alfa
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2022-502727-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502727-21-00.